{"title":"瑞典乌普萨拉地区10年figo - IA-IIB期宫颈癌的预后因素:人口队列研究","authors":"I. Skirnisdottir, Karina Varasteh","doi":"10.31487/j.aco.2022.02.03","DOIUrl":null,"url":null,"abstract":"Background: The incidence of cervical cancer in Sweden decreased to 8/100,000 in the year 2011 but has from 2014 increased to 11/100,000. The noted increase was, mainly observed in FIGO-stages IA-IB, where patients usually are asymptomatic and detected in screening. \nMaterials and Methods: The study population consisted of 253 patients with cervical carcinoma in FIGO-stages IA-IIB. The patients were referred to the Department of Gynecology at the Akademiska University Hospital in Uppsala for decision of treatment from 2008 to 2017. \nResults: Clinical and pathological features of cervical carcinoma were compared according to the subtypes: squamous cell carcinoma (n=150), adenocarcinoma (n=74) and adeno-squamous cancer (n=29). Other rare histological types (n = 6) were excluded. Finally, 207 (82%) out of the 253 referred patients, had primary surgical treatment and 29 (14%) patients had additional oncological treatment. The remaining 46 patients (18%) received primary oncological treatment. In the present study 45 (17.8%) developed recurrent disease. Prognostic factors for disease-free survival in Cox-regression analysis were stage (IA versus IIB) (p = 0.000) and histopathologic subtype (p = 0.009). In a survival analysis the disease-free survival differed between the histological subtypes; 62 % for squamous cell cancer in cervix, 48 % for adenocarcinoma, and 32 % for adeno-squamous cancer (Chi-square = 6,221; p = 0,045)). Logistic regression analysis including treatment details, showed no other predictive factors for recurrent disease. \nConclusion: The results from this study suggest that prognostic factors for disease-free survival are FIGO-stage (IA –IIB) and histopathology, but not tumor grade, age or choice of treatment.","PeriodicalId":320563,"journal":{"name":"Annals of Clinical Oncology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Factors for Cervical Cancer in FIGO-Stages IA-IIB in a 10-Year Period in the Region of Uppsala, Sweden: Population Cohort Study\",\"authors\":\"I. Skirnisdottir, Karina Varasteh\",\"doi\":\"10.31487/j.aco.2022.02.03\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The incidence of cervical cancer in Sweden decreased to 8/100,000 in the year 2011 but has from 2014 increased to 11/100,000. The noted increase was, mainly observed in FIGO-stages IA-IB, where patients usually are asymptomatic and detected in screening. \\nMaterials and Methods: The study population consisted of 253 patients with cervical carcinoma in FIGO-stages IA-IIB. The patients were referred to the Department of Gynecology at the Akademiska University Hospital in Uppsala for decision of treatment from 2008 to 2017. \\nResults: Clinical and pathological features of cervical carcinoma were compared according to the subtypes: squamous cell carcinoma (n=150), adenocarcinoma (n=74) and adeno-squamous cancer (n=29). Other rare histological types (n = 6) were excluded. Finally, 207 (82%) out of the 253 referred patients, had primary surgical treatment and 29 (14%) patients had additional oncological treatment. The remaining 46 patients (18%) received primary oncological treatment. In the present study 45 (17.8%) developed recurrent disease. Prognostic factors for disease-free survival in Cox-regression analysis were stage (IA versus IIB) (p = 0.000) and histopathologic subtype (p = 0.009). In a survival analysis the disease-free survival differed between the histological subtypes; 62 % for squamous cell cancer in cervix, 48 % for adenocarcinoma, and 32 % for adeno-squamous cancer (Chi-square = 6,221; p = 0,045)). Logistic regression analysis including treatment details, showed no other predictive factors for recurrent disease. \\nConclusion: The results from this study suggest that prognostic factors for disease-free survival are FIGO-stage (IA –IIB) and histopathology, but not tumor grade, age or choice of treatment.\",\"PeriodicalId\":320563,\"journal\":{\"name\":\"Annals of Clinical Oncology\",\"volume\":\"37 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31487/j.aco.2022.02.03\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/j.aco.2022.02.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic Factors for Cervical Cancer in FIGO-Stages IA-IIB in a 10-Year Period in the Region of Uppsala, Sweden: Population Cohort Study
Background: The incidence of cervical cancer in Sweden decreased to 8/100,000 in the year 2011 but has from 2014 increased to 11/100,000. The noted increase was, mainly observed in FIGO-stages IA-IB, where patients usually are asymptomatic and detected in screening.
Materials and Methods: The study population consisted of 253 patients with cervical carcinoma in FIGO-stages IA-IIB. The patients were referred to the Department of Gynecology at the Akademiska University Hospital in Uppsala for decision of treatment from 2008 to 2017.
Results: Clinical and pathological features of cervical carcinoma were compared according to the subtypes: squamous cell carcinoma (n=150), adenocarcinoma (n=74) and adeno-squamous cancer (n=29). Other rare histological types (n = 6) were excluded. Finally, 207 (82%) out of the 253 referred patients, had primary surgical treatment and 29 (14%) patients had additional oncological treatment. The remaining 46 patients (18%) received primary oncological treatment. In the present study 45 (17.8%) developed recurrent disease. Prognostic factors for disease-free survival in Cox-regression analysis were stage (IA versus IIB) (p = 0.000) and histopathologic subtype (p = 0.009). In a survival analysis the disease-free survival differed between the histological subtypes; 62 % for squamous cell cancer in cervix, 48 % for adenocarcinoma, and 32 % for adeno-squamous cancer (Chi-square = 6,221; p = 0,045)). Logistic regression analysis including treatment details, showed no other predictive factors for recurrent disease.
Conclusion: The results from this study suggest that prognostic factors for disease-free survival are FIGO-stage (IA –IIB) and histopathology, but not tumor grade, age or choice of treatment.